A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 31/337 (2006.01) A61K 31/7088 (2006.01)
Patent
CA 2408746
A method is described for improving the pharmacokinetics of a drug in a subject, by co-administering oligomers, preferably PMO's (phosphorodiamidate morpholino oligonucleotides), antisense to RNAs encoding drug-metabolizing enzymes, particularly p450 enzymes. The oligomers reduce production of the drug-metabolizing enzymes, which extends drug half-life and effectiveness and/or decreases drug toxicity.
L'invention concerne un procédé d'amélioration de la pharmacocinétique d'un médicament chez un sujet, par la co-administration d'oligomères, de préférence des PMO (oligonucléotides morpholino phosphorodiamidate), des ARN antisens codant pour des enzymes à métabolisation de médicaments, notamment des enzymes p450. Les oligomères réduisent la production des enzymes à métabolisation de médicaments, ce qui accroît la demi-vie du médicament et son efficacité et/ou diminue sa toxicité.
Gowling Lafleur Henderson Llp
The Board Of Regents Of The University Of Nebraska
LandOfFree
Antisense phosporodiamidate morpholino oligonucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense phosporodiamidate morpholino oligonucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense phosporodiamidate morpholino oligonucleotide... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1699426